Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Miraglia v. Human Genome Sciences, Inc. et al
Case Number:
8:11-cv-03231
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 26, 2013
Human Genome, GSK Dodge Lupus-Drug Suicide Suit
A Maryland federal judge on Tuesday dismissed a consolidated securities class action accusing Human Genome Sciences Inc. and GlaxoSmithKline PLC of concealing suicide risks associated with lupus drug Benlysta, saying the plaintiffs had failed to show the companies purposefully hid reported suicides from investors.
-
May 25, 2012
Human Genome Denies Hiding Suicide Risks In Lupus Drug Case
Biopharmaceutical firm Human Genome Sciences Inc. on Thursday asked a federal judge to scuttle proposed securities class actions accusing it of concealing suicide risks associated with lupus drug Benlysta, saying that investors cherry-picked the public record in a desperate attempt to build a case.